Wendi Qian

A Phase 3 Trial of Bevacizumab in Ovarian Cancer

Timothy Perren, Ann Marie Swart, Jacobus Pfisterer et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

Medicine, Oncology, Pharmacology +11

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

Gordon Rustin, Maria EL van der Burg, Clare Griffin et al. · The Lancet · 2010 · 594 citations · Full text

Medicine, Gynecology, Oncology +15

Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles

David Cunningham, Eliza A. Hawkes, Andrew Jack et al. · The Lancet · 2013 · 556 citations · Full text

Medicine, Oncology, Pharmacotherapy +14

High-Dose Therapy Improves Progression-Free Survival and Survival in Relapsed Follicular Non-Hodgkin’s Lymphoma: Results From the Randomized European CUP Trial

Harry C. Schouten, Wendi Qian, Stein Kvaløy et al. · Journal of Clinical Oncology · 2003 · 479 citations

Medicine, Hematology, Oncology +15

Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial

Kirit M. Ardeshna, Wendi Qian, Paul Smith et al. · The Lancet Oncology · 2014 · 388 citations

Medicine, Oncology, Pharmacotherapy +8